Notable surgical trials in gynecologic oncology: a 10-year overview.
| Autor: | Vilches JC; Department of Obstetrics and Gynecology, Hospital Quironsalud Malaga, Malaga, Spain jcvilches@sego.es., Santía MC; Obstetrics and Gynecology, Houston Methodist Hospital, Houston, Texas, USA., Yates EM; Obstetrics and Gynecology, Houston Methodist Hospital, Houston, Texas, USA., Pareja R; Gynecology, Gynecologic Oncology, Clinica ASTORGA, Medellin, and Instituto Nacional de Cancerología, Medellin, Colombia., Lozano M; Department of Obstetrics and Gynecology, Hospital Quironsalud Malaga, Malaga, Spain., Ramirez PT; Obstetrics and Gynecology, Houston Methodist Hospital, Houston, Texas, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2024 Aug 05; Vol. 34 (8), pp. 1273-1282. Date of Electronic Publication: 2024 Aug 05. |
| DOI: | 10.1136/ijgc-2024-005471 |
| Abstrakt: | In the last decade, we have witnessed important advances in novel therapeutics in the management of gynecologic cancers. These studies have built on the findings from preexisting data and have provided incremental contributions leading to changes that have not only impacted the accuracy of cancer detection and its metastatic components but also led to improvements in oncologic outcomes and quality of life. Key landmark trials have changed the standard of care in cervix, uterine, and ovarian cancer. A number of these have been controversial and have generated significant debate among gynecologic oncologists. The main objective of this review was to provide an overview on each of these trials as a reference for immediate and consolidated access to the study aims, methodology, results, and conclusion. Competing Interests: Competing interests: None declared. (© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|